InflaRx N.V. (IFRX) stock
IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.04−0.05 (-4.59%)
Close on Nov 20, 2026Market cap $75.18MP/E –Yield –
InflaRx gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
For fiscal 2025 it was -€7.24M. The highest annual figure on record is -€469.17K in fiscal 2023.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€7.24M | – |
| FY2024 | Dec 31, 2024 | -€3.15M | – |
| FY2023 | Dec 31, 2023 | -€469.17K | – |
| FY2018 | Dec 31, 2018 | -€37.82M | – |
| FY2017 | Dec 31, 2017 | -€19.55M | – |
| FY2016 | Dec 31, 2016 | -€7.12M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | -€2.36M | – |
| Q2 FY2024 | Jun 30, 2024 | -€341.80K | – |
| Q2 FY2019 | Jun 30, 2019 | -€16.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -€8.19M | – |
See a number that looks wrong?